Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 employees.Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is recognised for the excellence of its product pipeline covering therapeutic areas ranging from respiratory, cardiovascular to central nerve system medicines. In recent years, the company also successfully advanced its research in diseases including diabetes and tumors. In 2009, Boehringer Ingelheim posted net sales of EUR 12.7 billion while spending 21% of net sales in its largest business segment, Prescription Medicines, on research and development. For more information, visit

Boehringer Ingelheim RSS Channel

Title Filter      Display #  
# Article Title
1 Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin
2 Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy
3 Boehringer Ingelheim Statement on Hepatitis C drug development
4 Boehringer Ingelheim will make detailed clinical trial data available to the scientific community
5 Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
6 Boehringer Ingelheim receives East Bay Innovation Award
7 Crystal Bioscience and Boehringer Ingelheim announce multiple target antibody discovery collaboration
8 New study showed significant reduction in blood glucose with Linagliptin alone and in combination with metformin
9 Global Lung Cancer Coalition to identify patient challenges and improve support strategies in partnership with Boehringer Ingelheim
10 Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin
11 Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy
12 Pradaxa® (dabigatran etexilate) drives Boehringer Ingelheim's innovation promise in cardiovascular diseases
13 Benefits of Pradaxa® maintained in difficult to treat patients with atrial fibrillation and symptomatic heart failure
14 Results of new meta-analysis regarding CV events in linagliptin Phase 3 trials
15 Boehringer Ingelheim pioneers biopharmaceuticals move to China
16 Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"
17 Boehringer Ingelheim joins Structural Genomics Consortium
18 FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)
19 American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education
20 New findings from two studies support substantial benefit of Pradaxa®
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]